MiniMed Group Q1 2027 EPS Tops Expectations, Revenue Up 17% - Alphastreet
Surprise breakeven quarter. MiniMed Group, Inc. (NASDAQ:MMED) delivered a notable upside surprise in its Q1 2027 results, posting breakeven earnings of $0.0...
MiniMed Group Reports Breakeven Quarter, Revenue Up 17%
MiniMed Group, Inc. (NASDAQ: MMED) achieved a significant milestone in its Q1 2027 results, posting breakeven earnings of $0.00 per share, surpassing the Street’s expected loss of $0.17 per share. The medical device manufacturer generated $843.0M in revenue for the quarter, representing a 16.6% increase from the $723.0M recorded in Q1 2026.
Revenue Growth Driven by CGM Segment
The company’s Continuous Glucose Monitoring (CGM) segment led performance with $431.0M in revenue, up 19.9% year‑over‑year. This growth demonstrates continued momentum in this critical growth driver. The worldwide CGM attachment rate reached 69.0% for the quarter, reflecting strong adoption among the company’s insulin pump user base.
Operational Highlights
MiniMed sold 34,000 new pumps worldwide during the period, providing a pipeline for future CGM conversions and recurring revenue streams. The revenue expansion, coupled with the return to profitability, points to genuine operating leverage rather than merely cost‑cutting‑driven results.
Profitability Inflection Point
Transitioning from projected losses to breakeven marks a meaningful operational achievement as the firm scales its higher‑margin CGM business while maintaining growth investments. The earnings beat appears fundamentally sound, driven by robust 16.6% topline growth rather than aggressive expense reductions that could jeopardize long‑term positioning. Management’s ability to grow revenue at double‑digit rates while reaching breakeven validates the scalability of the business model.
Analyst Sentiment
Wall Street remains decidedly bullish, with consensus ratings of 10 buys, 2 holds and no sells. This overwhelmingly positive outlook reflects confidence in MiniMed’s competitive stance within the insulin delivery and monitoring markets. The muted stock reaction despite the earnings beat may indicate that investors are seeking sustained profitability over multiple quarters or stronger guidance to justify further multiple expansion.
Investor Considerations
The stock traded largely unchanged after the release, suggesting investors are evaluating the quality and durability of the profitability inflection. As MiniMed continues to scale its CGM business and sustain growth investments, market participants will watch closely for evidence of ongoing profitability and guidance that could drive future share‑price appreciation.
Source: news.alphastreet.com · 2026-09-01